Meta-analysis on the association between CYP2D6*10 gene polymorphism and disease free survival of breast cancer patients receiving tamoxifen treatment in Asia

Abstract

Literatures about case-control study on the association between CYP2D6*10 gene polymorphism and breast cancer were searched from last updated on May, 2014. Odds ratio of CYP2D6*10 gene distributions in breast cancer patients against healthy control were analyzed. STATA 12 software was applied for investigating hereogeneity among individual studies and summarizing effects across studies by proper statistical methods. A total of 812 cases (case group) and 323 cases (control group) were included. Disease free survival of breast cancer patients with CYP2D6*10 wild-type homozygous and heterozygous is higher than that of CYP2D6*10/*10 patients after the tamoxifen treatment, with statistical significance. Disease free survival of breast cancer patients with CYP2D6*10/*10 gene is similar to those with other genotypes after the tamoxifen treatment. This study demonstrated that CYP2D6*10 genotype is unlikely to have any clinical significance for prognosis of breast cancer patients receiving tamoxifen alone.

Keywords

• Breast cancer
• Tamoxifen
• CYP2D6*10
• Polymorphism
• Meta-analysis